Published in final edited form as:

Bioorg Med Chem Lett. 2018 July 15; 28(13): 2320–2323. doi:10.1016/j.bmcl.2018.05.015.

Chemical space screening around Phe³ in opioid peptides: modulating μ versus δ agonism by Suzuki-Miyaura cross-couplings

Tom Willemse^{a,e,†}, Emilie Eiselt^{b,†}, Karlijn Hollanders^{a,e}, Wim Schepens^c, Herman W.T. van Vlijmen^c, Nga N. Chung^d, Véronique Blais^b, Brain Holleran^b, Jean-Michel Longpré^b, Peter W. Schiller^d, Bert U.W. Maes^e, Philippe Sarret^{b,*}, Louis Gendron^{b,*}, and Steven Ballet^{a,*}

^aResearch Group of Organic Chemistry, Departments of Bioengineering Sciences and Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, Brussels 1050, Belgium

^bDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du CHUS, Université de Sherbrooke, 300112^e Avenue Nord, Sherbrooke, Quebec QC J1H 5N4, Canada

^cDiscovery Sciences, Janssen Research and Development, Turnhoutseweg 30, Beerse 2340, Belgium

^dLaboratory of Chemical Biology and Peptide Research, Montreal Clinical Research Institute, 110avenue des Pins Ouest, Montreal, Quebec H2W 1R7, Canada

^eOrganic Synthesis Division, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium

Abstract

In this study, affinities and activities of derivatized analogues of Dmt-dermorphin[1–4] (i.e. Dmt-D-Ala-Phe-GlyNH₂, Dmt = 2',6'-dimethyl-(*S*)-tyrosine) for the μ opioid receptor (MOP) and δ opioid receptor (DOP) were evaluated using radioligand binding studies, functional cell-based assays and isolated organ bath experiments. By means of solid-phase or solution-phase Suzuki-Miyaura cross-couplings, various substituted regioisomers of the phenylalanine moiety in position 3 of the sequence were prepared. An 18-membered library of opioid tetrapeptides was generated *via* screening of the chemical space around the Phe³ side chain. These substitutions modulated bioactivity, receptor subtype selectivity and highly effective ligands with subnanomolar binding affinities, contributed to higher functional activities and potent analgesic actions. In search of selective peptidic ligands, we show here that the Suzuki-Miyaura reaction is a versatile and robust tool which could also be deployed elsewhere.

Graphical Abstract

*Corresponding Authors: Steven Ballet, steven.ballet@vub.be, Philippe Sarret, philippe.sarret@USherbrooke.ca, Louis Gendron, louis.gendron@USherbrooke.ca.

[†]equal contribution

Keywords

Opioid peptides; GPCR ligands; Non-natural amino acids; Suzuki-Miyaura cross coupling; Receptor Selectivity

Alleviation or treatment of pain remains a significant challenge in pain research. Although opioid therapy is the cornerstone of severe and chronic pain management, serious unwanted effects are associated with their (chronic) administration (e.g., physical dependence, tolerance, nausea).¹ The biological effects of these drugs are exerted via binding to the three opioid receptor subtypes (μ -, δ -, and κ -opioid receptors termed MOP, DOP and KOP, respectively), belonging to the superfamily of G protein-coupled receptors.^{2, 3} One possible approach to overcome the limitations of opioids is the use of ligands with mixed activity profile.⁴ It has, for example, previously been shown that dual MOP/DOP agonism or mixed agonism/antagonism were advantageous over highly-selective receptor subtype ligands.^{5–11}

The opioid heptapeptidedermorphin (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂), initially derived from the skin of the South American frog *Phyllomedusa sauvagei*, was found to be a potent and selective MOP agonist.^{12–14} Compared to morphine, dermorphin was shown to possess higher antinociceptive efficacy with decreased adverse effects.¹⁵ SAR studies indicated the *N*-terminal tetrapeptide to be the minimal sequence required for potent opioid responses. In addition, it had been shown that Dmt¹ replacement of tyrosine afforded ligands with enhanced MOP and DOP bioactivity.¹⁶ Here, we attempted to modulate the pharmacological profiles of the peptidic ligands by modifying the second key aromatic pharmacophore group, the Phe³ side chain. It was hypothesized that the Dmt¹ residue of the opioid peptide would reach deeply into the orthosteric binding pockets, while the Phe³ side chain would position itself at the outer boundaries of the binding pocket of the receptors. For DOP, the Phe³ side chain reaches a potential subpocket created by the side chains of H³⁰¹, K¹⁰⁸, Y¹⁰⁹, E¹¹² and V¹⁹⁷. In case of MOP, the side chain may access a pocket defined by the side chains of Q¹²⁴, H³¹⁹, W³¹⁸ and I³²², and hence in both cases additional hydrophobic, dipole-dipole and cation- π interactions could for instance be made between ligand and receptor by substituting the second aromatic ring in opioid peptides.

In the present work, we report the synthesis and the *in vitro/in vivo* biological evaluation of potent opioid peptide ligands with mixed MOP/DOP activity profile by extension of the Phe³ aromatic core. Introduction of a 'halogen derivatization handle' allowed structural modification via Suzuki-Miyaura cross-couplings.^{17, 18}

This robust C-C coupling allows the efficient introduction of substituents on arylated amino acid residues in peptide substrates.^{19–23} Previously, this bioorthogonal methodology has been applied for the derivatization of peptides,^{24–28} leading to altered biological profile and

therapeutic effect^{27, 29} implementing both solution-phase²¹ and solid-phase^{30–33} Suzuki-Miyaura reactions. The functional group compatibility of Suzuki-Miyaura reactions with peptidic substrates has recently been reviewed elsewhere.^{22, 27}

The commercial availability of the different regioisomers of iodo-(*S*)-phenylalanine and straightforward incorporation into opioid tetrapeptides provided, after derivatization, a diverse library including (hetero)aromatic or vinylic substituents (Figure 1) and imposed profound effects on the biological activity. The dermorphin(1–4) analogues **1–9** were prepared via standard N_{α} -Fmoc-based solid phase peptide synthesis using Rink Amide resin as solid support. The Dmt¹ residue was inserted as Boc-Dmt-OH (2 eq), and with DIC/HOBt (each 2 eq) to avoid acylation on the unprotected phenol moiety. The Suzuki-Miyaura reactions, making use of (hetero)aromatic boronic acids as coupling partners, were performed on the solid support bearing the fully protected halogenated tetrapeptides (Scheme 1).

Catalyst screening showed that the PdCl₂(dppf) catalyst, which was shown to be compatible to peptide diversification in solution phase,²² allowed to prepare the cross-coupled products with excellent conversions on support. Hence, the cross-couplings on solid-phase were realized with PdCl₂(dppf) (10 mol%) as the precatalyst system in combination with K₂CO₃ (5 eq) and (hetero)aromatic boronic acids (3 eq). Near complete conversions were attained after 30 min in a mixture of THF/H₂O (1/1) at 100°C, while gently stirring the resin beads in MW vials. After successful cross-coupling, the peptide analogues were cleaved from the resin by treatment with a mixture of TFA/TES/H₂O (95:2.5:2.5 v/v/v). The crude peptides were obtained after evaporation of the cleavage mixture and purified by preparative HPLC to yield the target peptides (>95% purity).

Due to the occurrence of side product formation during cleavage, a different strategy was pursued to access the vinylated analogues. The vinyl group was chosen as a substituent of limited size which additionally offers a possibility for further diversification or peptide cyclization. Here, the peptides were first assembled on solid support and cleaved to obtain the iodinated precursor peptides (Scheme 1). As mentioned above, this (still convergent) strategy was followed due to the limited stability of vinylated products toward highly acidic (95% TFA) conditions. After optimization of the reaction conditions, PdCl₂(dppf) (5mol%) was again found suitable for these transformations in combination with K₂CO₃ (6 eq) as the base and potassium vinyltrifluoroborate (3 eq) as the boron coupling partner. For these couplings trifluoroborates, bench-stable analogues of boronic acid, were used.^{34, 35} In this case, optimal conversion was reached in a 1:1 mixture of H₂O/*i*PrOH at 80°C for 2 hours. The peptides were obtained after purified by preparative HPLC with a yield ranging from 13–39% (>95% purity).

The obtained set of peptide analogues (**1–9**) was evaluated for biological activity (see Table 1). In addition to MOP and DOP binding and functional signaling bioassay (EPAC cAMP BRET-based biosensor test), the guinea pig ileum (GPI, functional test representative of MOP agonist activity) and mouse vas deferens (MVD, functional test representative of DOP agonist activity) assays were carried out. From this first data set, it could be concluded that the peptides with highest MOP and DOP agonist activity contained a substituent at the

ortho-position (**3**, **6**, **9**). Especially the vinyl group (**9**) attracted interest due to its subnanomolar binding affinity for MOP and its potent activity in the functional bioassays. Indeed, compound **9** exhibited respectively 20-fold and 70-fold increase in potency at inhibiting cAMP production and GPI contraction, compared to the reference MOP agonist DAMGO (Tables 1 and 2).

Interestingly, two peptides with *para*-substitution (**1**, **4**) demonstrated *in vitro* μ -opioid antagonism in the functional GPI assay and analogues **1**, **2**, **4** and **5** behaved as δ partial agonists in the MVD assay. This antagonism or partial agonism of the 4'-substituted ligands could be shifted to improved agonist activity by either *meta*- or *ortho*-substitution, with the latter giving way to the most potent compounds (i.e., for **3/6/9**). Such a tendency was noticed for both MOP and DOP. Activities in both assays were highest for the *ortho*-substituted tetrapeptides, which clearly shows the benefit of these focused derivatizations realized by the Suzuki-Miyaura reaction. Based on these findings, we focused our efforts on more subtle structural changes at the *ortho*-position of the Phe³ side chain, providing ligands **10–18**.

Additionally, we envisaged the substitution of the D-Arg² residue by D-Ala² (**15–17**) could influence these profiles and potentially enhanced hydrophobicity could be reached by insertion of *N*Me-D-Ala (**18**). The biological results of this second subset of compounds are summarized in Table 2. Moreover, both parent peptides (with either D-Arg (**19**) or D-Ala (**20**)), were included in Table 1 for comparison. Remarkably, all ligands with the exception of compound **16** were highly selective for the MOP and showed subnanomolar affinities. Of note, up to a 7-fold increase in affinity could be observed through minor changes (such as CF₃ group *versus* F). Tetrapeptide **11** possessed the highest affinity, showing an IC₅₀ of 70 pM.

Replacement of D-Arg by D-Ala (**15/16/17** vs. **3/6/9**, resp.) had a marginally positive effect, except for **16** which, unexpectedly, showed poor affinity for MOP. Very high MOP over DOP selectivity was obtained for ligand **14**, indicating that very subtle changes, such as methyl group insertions, can induce a profound effect on the opioid receptor selectivity. Likewise, compounds **11–13** carrying an *ortho*-substitution on the aromatic side chain, exhibited improved selectivity for MOP over DOP.

Similarly, parent ligands **19** and **20** also resulted in higher affinity for the MOP receptor (10-fold increase compared to DAMGO), a result which is to be expected since they originate from the MOP-selective dermorphin. In the EPAC cAMP BRET-based biosensor assay, selected examples of the second tetrapeptide set were very potent in reducing cAMP production (Table 2). Overall, these results revealed strong correlation between binding and functional data.

The analgesic effectiveness of selected compounds was then evaluated using the tail-flick test on rats after intrathecal administration. Our results revealed that compounds **14** and **15**, as well as their respective parent peptides **19** and **20**, showing either high-affinity for both receptors or selectivity at MOP, exerted potent analgesic action on thermal nociception for times exceeding 60 min (Figure 3). Importantly, these analgesic effects were 10 times more

effective in reversing the nociceptive behavior than DAMGO, a selective and potent MOP agonist, used as the reference compound.

In conclusion, a series of truncated and derivatized dermorphintetrapeptide analogues was prepared by means of the Suzuki-Miyaura reaction. Straightforward introduction of (hetero)aromatic and vinylic substituents was realized, allowing a spatial screening of the chemical space around the Phe³ side chain. Depending on the position and size of the newly incorporated substituent, different pharmacological profiles were accessed, with some of the ligands even possessing picomolar binding affinities for MOP. After intrathecal administration, some selected analogues (compounds **14** and **15**) were also very effective in reducing the withdrawal nociceptive responses to thermal stimuli in rats. A potential binding pose of derivatized ligand **15** is provided in the supporting information. Given the increased hydrophobicity of the derivatized ligands (see supporting information for a comparison of cLogP values and HPLC retention times), the described ligands have potentially improved pharmacokinetic properties, and increased absorption after systemic administration may result. In due time, the antinociceptive effect of the derivatized ligands after peripheral administration will be reported and compared to the parent structures. Moreover, the described ligands could possibly profit from an increased metabolic stability, after derivatization by the Suzuki-Miyaura reaction, since they encompass unnatural amino acid derivatives. Hence, the described derivatization approach could also be applied elsewhere in view of the above advantages.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the Agency Flanders Innovation and Entrepreneurship (VLAIO) and Janssen Pharmaceutica for financial support of T.W. L.G. and P.S. thank the Canadian Institutes of Health Research (CIHR) for supporting their re-search (MOP-123399, MOP-136871, FDN-148413). L.G. is the recipient of a Chercheur-boursier Senior from the Fonds de la Recherche du Québec-Santé (FRQS). P.S. holds the Tier 1 Canada Research Chair in Neurophysiopharmacology of Chronic Pain. The work of P.W.S. was supported by NIH grant DA004443 and CIHR grant MOP-89716.

Abbreviations

BRET	bioluminescence resonance energy transfer
cAMP	cyclic adenosine monophosphate
Dmt	2,6-dimethyltyrosine, DOP, δ -opioid receptor
EC₅₀	Half maximal effective concentration
EPAC	exchange protein directly activated by cAMP
GPI	guinea pig ileum
IC₅₀	half maximal inhibitory concentration

K_i	inhibitory constant
KOP	κ-opioid receptor
MOP	μ-opioid receptor
MVD	mouse vas deferens
P.A	partial agonist
TES	triethylsilane

References and notes

- Pasternak GW. Neuropharmacology. 2014; 76:198–203. [PubMed: 23624289]
- Waldhoer M, Bartlett SE, Whistler JL. Annu Rev Biochem. 2004; 73:953–990. [PubMed: 15189164]
- Udenfriend, S., Meienhofer, J. Opioid Peptides: Biology, Chemistry, and Genetics: The Peptides: Analysis, Synthesis, Biology. Elsevier; 1984.
- Turnaturi R, Arico G, Ronsisvalle G, Parenti C, Pasquinucci L. Eur J Med Chem. 2016; 108:211–228. [PubMed: 26656913]
- Schiller PW, Fundytus ME, Merovitz L, et al. J Med Chem. 1999; 42:3520–3526. [PubMed: 10479285]
- Lee YS, Petrov R, Park CK, et al. J Med Chem. 2007; 50:5528–5532. [PubMed: 17927164]
- Ananthan, S. Opioid Ligands with Mixed μ/δ Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics. In: Rapaka, RS., Sadée, W., editors. Drug Addiction: From Basic Research to Therapy. Springer; New York, New York, NY: 2006. p. 367–380.
- Mollica A, Davis P, Ma SW, Porreca F, Lai J, Hruby VJ. Bioorg Med Chem Lett. 2006; 16:367–372. [PubMed: 16275086]
- Balboni G, Guerrini R, Salvadori S, et al. J Med Chem. 2002; 45:713–720. [PubMed: 11806723]
- Yamazaki M, Suzuki T, Narita M, Lipkowski AW. Life Sci. 2001; 69:1023–1028. [PubMed: 11508644]
- Vandormael B, Fourla DD, Gramowski-Voß A, et al. J Med Chem. 2011; 54:7848–7859. [PubMed: 21978284]
- Broccardo M, Erspamer V, Falconieri G, et al. Br J Pharmacol. 1981; 73:625–631. [PubMed: 7195758]
- Montecucchi PC, Castiglione R, Piani S, Gozzini L, Erspamer V. Int J Pept Protein Res. 1981; 17:275–283. [PubMed: 7287299]
- Steel R, Timms M, Levina V, Vine J. Drug Test Anal. 2014; 6:909–921. [PubMed: 24259424]
- Melchiorri P, Negri L. General Pharmacology: The Vascular System. 1996; 27:1099–1107. [PubMed: 8981054]
- Hansen DW Jr, Stapelfeld A, Savage MA, et al. J Med Chem. 1992; 35:684–687. [PubMed: 1311764]
- Miyaura N, Suzuki A. Chem Rev. 1995; 95:2457–2483.
- Suzuki A. Angew Chem Int Ed. 2011; 50:6722–6737.
- Limbach M, Löweneck M, Schreiber JV, Frackenpohl J, Seebach D, Billich A. Helv Chim Acta. 2006; 89:1427–1441.
- Kotha S, Lahiri K. Bioorg Med Chem Lett. 2001; 11:2887–2890. [PubMed: 11597423]
- Vilaró M, Arsequell G, Valencia G, Ballesteros A, Barluenga J. Org Lett. 2008; 10:3243–3245. [PubMed: 18598051]
- Willemse T, Van Imp K, Goss RJ, et al. Chem Cat Chem. 2015; 7:2055–2070.
- Chalker JM, Wood CS, Davis BG. J Am Chem Soc. 2009; 131:16346–16347. [PubMed: 19852502]

24. Stevenazzi A, Marchini M, Sandrone G, Vergani B, Lattanzio M. *Bioorg Med Chem Lett*. 2014; 24:5349–5356. [PubMed: 25455481]
25. King M, Wagner A. *Bioconjugate Chem*. 2014; 25:825–839.
26. Antos JM, Francis MB. *Curr Opin Chem Biol*. 2006; 10:253–262. [PubMed: 16698310]
27. Willemse T, Schepens W, van Vlijmen HW, Maes BU, Ballet S. *Catalysts*. 2017; 7:74.
28. Lang K, Chin JW. *ACS Chem Biol*. 2014; 9:16–20. [PubMed: 24432752]
29. Mapelli C, Natarajan SI, Meyer JP, et al. *J Med Chem*. 2009; 52:7788–7799. [PubMed: 19702274]
30. Castanedo GM, Sailes FC, Dubree NJ, et al. *Bioorg Med Chem Lett*. 2002; 12:2913–2917. [PubMed: 12270174]
31. Haug BE, Stensen W, Svendsen JS. *Bioorg Med Chem Lett*. 2007; 17:2361–2364. [PubMed: 17350833]
32. Nielsen TE, Le Quement S, Meldal M. *Tetrahedron Lett*. 2005; 46:7959–7962.
33. Ng-Choi I, Soler M, Cerezo V, et al. *Eur J Org Chem*. 2012; 2012:4321–4332.
34. Molander GA, Ellis N. *Acc Chem Res*. 2007; 40:275–286. [PubMed: 17256882]
35. Lennox AJ, Lloyd-Jones GC. *Chem Soc Rev*. 2014; 43:412–443. [PubMed: 24091429]

A. Supplementary data

The Supporting data associated with this article can be found, in the online version, at <http://dx.doi.org/>

Figure 1.
Phe³ derivatizations within the opioid tetrapeptides H-Dmt¹-D-Arg²-Phe³-Gly⁴-NH₂

Figure 2.
Structures of the second set [Dmt¹, D-Arg²]- and [Dmt¹, D-Ala²]dermorphin(1–4) analogues

Figure 3.
Analgesic effects of selected *ortho*-substituted Phe³ opioid tetra-peptides **14** and **15**.

Scheme 1.

Preparation of the first peptide set using on-resin and off-resin Suzuki-Miyaura cross-couplings

Table 1
Affinity and *in vitro* functional activity data for the first set of diversified opioid tetrapeptides

Peptides	MOP IC ₅₀ (nM)	DOP IC ₅₀ (nM)	Selectivity IC ₅₀ ^d /IC ₅₀ ^a	IC ₅₀ (GPI) (nM)	IC ₅₀ (MVD) (nM)
MOP-selective DAMGO	1.39±0.3	1533±172	/	28.3	950
DOP-selective DeltII	627±100	1.00±0.14	/	854	0.147
Dmt-D-Arg-Phe(4-phenyl)-Gly-NH ₂ 1	7.08±3.34	42.3±35	6	K _e = 114 ±21 <i>I</i>	3090±340 (P.A. IC ₅₀)
Dmt-D-Arg-Phe(3-phenyl)-Gly-NH ₂ 2	0.85±0.15	268.8±237	316	61.7±3.9	117 ±15 (P.A. IC ₅₀)
Dmt-D-Arg-Phe(2-phenyl)-Gly-NH ₂ 3	0.54±0.16	20.25±2.31	38	3.47±0.06	6.99±0.69
Dmt-D-Arg-Phe(4-(3-thienyl))-Gly-NH ₂ 4	5.04±4.1	309±19.2	61	K _e = 138 ±21 <i>I</i>	3960±190 (P.A. IC ₅₀)
Dmt-D-Arg-Phe(3-(3-thienyl))-Gly-NH ₂ 5	1.03±0.05	601±536	583	30.4±3.8	52.8±4.6 (P.A. IC ₅₀)
Dmt-D-Arg-Phe(2-(3-thienyl))-Gly-NH ₂ 6	1.45±0.5	625±18	431	1.54±0.25	2.75±0.37
Dmt-D-Arg-Phe(4-vinyl)-Gly-NH ₂ 7	1.82±0.14	1415±282	777	24.1±2.6	430±13
Dmt-D-Arg-Phe(3-vinyl)-Gly-NH ₂ 8	0.46±0.17	165±19.8	359	1.43±0.12	9.74±1.17
Dmt-D-Arg-Phe(2-vinyl)-Gly-NH ₂ 9	0.47±0.23	18±4.46	38	0.389±0.062	0.406±0.038
Dmt-D-Arg-Phe(2-(4-MeO-phenyl))-Gly-NH ₂ 10	0.47±0.24	70.2±27.2	149	0.901±0.224	5.23±0.28
Dmt-D-Arg-Phe(2-(4-CF ₃ -phenyl))-Gly-NH ₂ 11	0.07±0.09	39.2±17	560	1.26±0.17	1.78±0.32
Dmt-D-Arg-Phe(2-(4-F-phenyl))-Gly-NH ₂ 12	0.47±0.06	435±26	925	0.801±0.086	2.95±0.26
Dmt-D-Arg-Phe(2-(4-Cl-phenyl))-Gly-NH ₂ 13	0.35±0.06	346±10	989	2.39±0.09	1.63±0.22
Dmt-D-Arg-Phe(2-(2-methyl-1-propenyl))-Gly-NH ₂ 14	0.57±0.15	585±10	1026	0.701±0.114	0.630±0.113
Dmt-D-Ala-Phe(2-phenyl)-Gly-NH ₂ 15	0.35±0.2	19.8±4.8	57	1.60±0.12	2.60±0.41
Dmt-D-Ala-Phe(2-(3-thienyl))-Gly-NH ₂ 16	240±73	687±188	4	1.27±0.16	2.16±0.45
Dmt-D-Ala-Phe(2-vinyl)-Gly-NH ₂ 17	0.25±0.05	8±1.9	32	1.18±0.17	2.81±0.37
Dmt-N-Me-D-Ala-Phe(2-vinyl)-Gly-NH ₂ 18	0.36±0.09	59.4±0.8	165	0.641±0.045	0.689±0.060
Dmt-D-Arg-Phe-Gly-NH ₂ 19	0.1±0.06	14±2.7	140	2.26±0.37	0.316±0.059
Dmt-D-Ala-Phe-Gly-NH ₂ 20	0.14±0.05	22.6±4.6	161	1.50±0.12	1.15±0.15

I: antagonist. P.A.: partial agonist. Binding affinities of compounds for MOP and DOP receptors were determined by competition binding studies of [¹²⁵I]-DAMGO (MOP-selective) and [¹²⁵I]-Deltorphin II (DOP-selective) using membrane preparations of HEK293 cells expressing MOP or DOP. The GPI functional assay is representative of MOP activation, whereas the MVD is a DOP-representative assay.

Table 2

EPAC cAMP BRET-based biosensor assay used to determine the potency (EC₅₀) of selected ligands at activating DOP and MOP.

Peptide	EPAC MOP EC ₅₀ (nM)	EPAC DOP EC ₅₀ (nM)
DAMGO	0.26±0.07	49±32.9
DeltII	16±12.3	0.1±0.04
6 with R= 2-(3-thienyl)	0.04 ± 0.03	49 ± 33
9 with R = 2-vinyl	0.012 ± 0.001	7 ± 2.896
11 with R = 2-(4-CF ₃ -phenyl)	0.12 ± 0.05	26.8 ± 6
14 with R = 2-methyl-1-propenyl	0.1 ± 0.4	19.4 ± 12.8
15 with R ² = 2-phenyl	0.12 ± 0.01	4.9 ± 1
16 with R ² = 2-(3-thienyl)	34.8 ± 6.3	56 ± 127 ^a
17 with R ² = 2-vinyl	0.006 ± 0.001	5.8 ± 1
18 with R ² = 2-vinyl	0.003 ± 0.004	4.4 ± 2
Dmt-D-Arg-Phe-Gly-NH ₂ 19	0.008 ± 0.002	1.13 ± 0.2
Dmt-D-Ala-Phe-Gly-NH ₂ 20	0.012 ± 0.0007	2.4 ± 1

^aPartial agonist (E_{max}: 70%)